Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus.

Elens, Laure;Sombogaard, Ferdi;Hesselink, Dennis A;van Schaik, Ron H N;van Gelder, Teun
(2013) Pharmacogenetics and Genomics —

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 477.6 KB
Request a copy

Details

Authors
  • Elens, LaureUCLouvain
    Author
  • Sombogaard, Ferdi
    Author
  • Hesselink, Dennis A
    Author
  • van Schaik, Ron H N
    Author
  • van Gelder, Teun
    Author
Abstract
New-onset diabetes after transplantation (NODAT) is an important complication after kidney transplantation. The etiology of the malady is multifactorial and includes both environmental and genetic factors. NODAT is a polygenic disease and many single-nucleotide polymorphisms could constitute potential risk factors. Peroxisome proliferator-activated receptor α (PPARα) and P450 oxidoreductase (POR) play a central role in the control of energy metabolism in humans. Some recent data highlighted a possible functional impact of two single-nucleotide polymorphisms in PPARα (rs4253728 G>A and rs4823613 A>G) and one coding variant in POR (rs1057868; POR*28; A503V) on the activity of their respective encoded proteins. In the present study, we assessed the association between these variants and the risk of developing NODAT after kidney transplantation.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Elens, L., Sombogaard, F., Hesselink, D. A., van Schaik, R. H. N., & van Gelder, T. (2013). Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Pharmacogenetics and Genomics. https://doi.org/10.1097/FPC.0000000000000001